What to ask when joint claims sound too certain

What to ask when the X-ray says bone on bone

Ask whether the worn spot matches where your knee hurts. Then ask about motion, strength, and whether the knee gives way. The X-ray matters, but it doesn't choose care for you. Sleep, walking, swelling, and stairs show the daily burden.

Exercise, a brace, a cane, or medicine may still help. Those choices won't fit every person or every joint. Surgery may be fair when you've tried them and still struggle. Your whole exam gives a clearer answer.

What to ask about a newer treatment

Ask what goes into the joint and who prepares it. Also ask what change is realistic and when you'd notice it. Less soreness doesn't mean cartilage grew back. A certain-result promise isn't honest.

After an exam, QC Kinetix may discuss PRP, a regenerative treatment made by spinning your blood to collect platelets. During the visit, staff place that platelet concentrate inside the sore joint. In a large knee study, PRP gave no more soreness relief than a salt-water shot and didn't slow cartilage loss. Hip and shoulder research is thinner, so knee results don't settle those joints.

Sources

1. The Lancet's osteoarthritis Seminar states that the diagnosis of osteoarthritis is clinically based despite the widespread OVERUSE of imaging methods, that management should be tailored to the individual and focus on core treatments including self-management and education, exercise and weight loss as relevant, and that surgery should be reserved for those who have not responded appropriately to less invasive methods.

   Hunter DJ, Bierma-Zeinstra S. — Osteoarthritis.. The Lancet, 2019. DOI: 10.1016/S0140-6736(19)30417-9.

2. A 2021 JAMA review states that osteoarthritis affects an estimated 240 million people worldwide including more than 32 million in the US, that 33% of people older than 75 have symptomatic and radiographic knee OA, that diagnosis is clinical despite widespread overuse of imaging, that people with OA are more sedentary and carry a 20% higher age-adjusted mortality, and that the cornerstones of management are exercise, weight loss where appropriate and education, complemented by topical or oral NSAIDs, with opiates to be avoided.

   Katz JN, Arant KR, Loeser RF. — Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review.. JAMA, 2021. DOI: 10.1001/jama.2020.22171.

3. A systematic review of prospective studies in unselected osteoarthritis patients found that the proportion reporting an unfavourable long-term pain outcome ranged from about 7% to 23% after hip replacement and 10% to 34% after knee replacement; in the best-quality studies, 9% or more after hip and about 20% after knee replacement.

   Beswick AD, Wylde V, Gooberman-Hill R, et al. — What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients.. BMJ Open, 2012. DOI: 10.1136/bmjopen-2011-000435.

4. A BMJ Rapid Recommendations panel issued a clinical practice guideline on arthroscopic surgery for degenerative knee arthritis and meniscal tears, published in The BMJ in 2017 and republished in the British Journal of Sports Medicine in 2018.

   Siemieniuk RAC, Harris IA, Agoritsas T, et al. — Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline.. BMJ, 2017. DOI: 10.1136/bmj.j1982.

5. The RESTORE trial randomised 288 community-based participants aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence grade 2 or 3) to three weekly intra-articular injections of leukocyte-poor PRP or saline placebo, with participants, injectors and assessors all blinded. 93% completed the 12-month follow-up. PRP did not produce a clinically meaningful improvement in knee pain over placebo, and did not slow medial tibial cartilage volume loss on MRI.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

6. A systematic review and meta-analysis of 169 randomised trials (21,163 participants) of viscosupplementation for knee OA found clear evidence of small-study effects and publication bias. The prespecified main analysis, restricted to 24 large placebo-controlled trials with at least 100 participants per group (8,997 randomised), found a pain reduction of SMD -0.08 (95% CI -0.15 to -0.02) - the confidence interval excluding the prespecified minimal clinically important difference of -0.37.

   Pereira TV, Jüni P, Saadat P, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

7. FDA states directly that regenerative medicine therapies - including stem cells, stromal vascular fraction, umbilical cord blood, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes - have NOT been approved for the treatment of any orthopedic condition, naming osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain. FDA further states that being charged for these products, or being offered them outside an FDA-overseen clinical trial, means a patient is likely being deceived and offered a product illegally, and that a product's presence on clinicaltrials.gov or a firm's FDA registration does not mean the product is legally marketed. Reported harms include blindness, tumor formation, neurological events and life-threatening bacterial infections.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Important Patient and Consumer Information About Regenerative Medicine Therapies. FDA.gov, 2021.